Aet Stats & Data
CCC(CC1=CNC2=CC=CC=C21)NZXUMUPVQYAFTLF-UHFFFAOYSA-NPharmacology
DrugBankDescription
In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was an FDA approved antidepressant under the name Monase. However, in 1962, after the discovery of an unacceptable incidence of agranulocytosis, the development of Monase was halted and the drug was withdrawn from potential market use. In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's. Currently, αET is an illegal substance; however, it's activity is still under scientific investigation. αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. Instead, the effects of αET, a tryptamine derivative, more closely resemble the amphetamine derived drug 3,4-methylenedioxy-N-methylamphetamine (MDMA). Similarly to MDMA, αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine. Like MDMA, increases in locomotor activity and mood elevation can be seen post administration.
Mechanism of Action
The mechanism of action responsible for its antidepressant activity was believed to lie in its ability to inhibit monoamine oxidase, while its stimulant activity on the central nervous system appeared to result from its structural similarity to indole-based psychedelics. Research discovered αET to be both a monoamine oxidase inhibitor and a potent monoamine releasing agent capable of serotonergic neurotoxicity. The ability to release serotonin was linked to αET's MDMA like properties. αET has been shown to release serotonin pre-synaptically, as well as lesser amounts of norepinephrine and dopamine.
Pharmacodynamics
αET is a stimulant and psychedelic with MDMA like physiological effects. Like MDMA, increases in locomotor activity and mood elevation can be seen post administration.
Indication
Developed in the 1960's for use as an antidepressant before market withdrawal in 1962.
Effect Profile
Curated + 3 ReportsLow visuals and headspace with mild body load
Strong stimulation and sensory enhancement with low empathy and euphoria
Mild stimulation with strong anxiety/jitters, low euphoria and focus
Community Effects
TripSitTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Too few reports for a chart: gender is known from 7 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?
- Male 7 of 7
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 3 experience reports (3 single-substance Erowid)
Effect Sentiment Distribution
Confidence Distribution
Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.
Too few reports for bars: these effects come from 3 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
Positive Effects 1
Adverse Effects 0
Real-World Dose Distribution
ErowidFrom 6 of 7 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.
Oral (n=6)
Form / Preparation
Most common forms and preparations, as a share of the 6 reports that give one
Too few reports for bars: these forms come from 6 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?
- Capsule 4 of 6